Breaking Finance News

A statement released earlier today by H.C. Wainwright about Mirna Therapeutics (NASDAQ:MIRN) drops the target price to $2.00

Yesterday Mirna Therapeutics (NASDAQ:MIRN) traded 1.00% higher at $1.96. The company’s 50-day moving average is $3.11 and its 200-day moving average is $4.10. The last stock close price is down -50.73% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time. 28,110 shares of the stock were exchanged, up from an average trading volume of 26,870

In a statement issued on Friday September 23, 2016 H.C. Wainwright reduced the stock price target of Mirna Therapeutics (NASDAQ:MIRN) from $6.00 to $2.00 indicating a possible upside of 0.02%.

Previously on 9/22/2016, Citigroup reported about Mirna Therapeutics (NASDAQ:MIRN) lowered the target price from $4.50 to $2.00. At the time, this indicated a possible downside of -0.01%.

See Chart Below

Mirna Therapeutics (NASDAQ:MIRN)

Mirna Therapeutics has a 52 week low of $1.82 and a 52 week high of $11.01 The company’s market cap is currently $0.

In addition to H.C. Wainwright reporting its target price, a total of 4 firms have reported on the stock. The consensus target price is $11.00 with 3 firms rating the stock a strong buy, 1 firm rating the stock a buy, 0 firms rating the stock a hold, 0 firms rating the stock a underperform, and finally 0 firms rating the stock a sell.

About Mirna Therapeutics (NASDAQ:MIRN)

Mirna Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of micro ribonucleic acid (RNA)-based oncology therapeutics. The Company is developing mimics of naturally occurring microRNAs that are designed to restore the tumor suppressor activity and aid appropriate anti-tumor immune response. This approach is known as microRNA replacement therapy. Its lead product candidate, MRX34, a mimic of naturally occurring microRNA-34 (miR-34) encapsulated in a liposomal nanoparticle formulation, has demonstrated clinical proof of concept as a single agent in its ongoing Phase I clinical trial. The Company's RNA molecules function as natural microRNAs when they enter human cells. These RNA molecules, which it calls microRNA mimics, may be used to replace those tumor suppressor microRNAs that are lost, or under expressed, in cancer cells. Its other preclinical product candidates include miR-215, miR-101, miR-16 and let-7.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.